"This discovery is a huge step forward in our efforts to prevent dementia and neurovascular diseases." ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating ...

A comprehensive study spanning a decade shed new light on the treatment of dementia with Lewy bodies (DLB), a condition that significantly impacts older adults. The research, published in Alzheimer’s ...

BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent ...

There is currently no cure for dementia with Lewy bodies, which is the 2nd most common type of dementia. Researchers from the Karolinska Institutet have found that Alzheimer’s disease medications ...

Nilotinib (Tasigna) — a drug for myeloid leukemia — improved biomarkers and cognitive outcomes in study participants with dementia with Lewy bodies, a new study finds. The phase II trial was small, ...

Proteins form the building blocks of life, but when they form unusual clumps inside the brain, they raise an alarm that ...

While Alzheimer’s disease is the most common type of dementia, there’s another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US. It is ...

In patients with dementia with Lewy bodies, those taking acetylcholinesterase inhibitors (with or without memantine) had a significantly lower risk of death and reduced length of hospital stay due to ...